Support teaching, research, and patient care.
Richard B. Moss, MD, is former chief of the Pediatric Pulmonary and Allergy Divisions, and allergy-immunology and pulmonary fellowship training programs director, at Stanford University. He was educated at Columbia (BA), SUNY Downstate (MD), Northwestern/Children’s Memorial Hospital (pediatrics residency) and Stanford (allergy-immunology, pulmonology fellowships). He was Director of the Cystic Fibrosis Center at Stanford (1991-2009) and site principal investigator for the Cystic Fibrosis Therapeutics Development Network (1999-2009), where he was also inaugural Chair of the Protocol Review Committee. He currently is a member of Stanford’s Child Health Research Institute, serves on the Pediatric Mentoring Program at Stanford, the Executive Committee of Stanford’s NIH clinical research program (Spectrum Child Health) and the Stanford IRB. Dr. Moss has reviewed and consulted for the NIH, CFF, national and international foundations, peer-review journals and biopharmaceutical companies. His research interests include immunopathogenesis, outcome measures, and treatment of chronic airway diseases of childhood. Recent work has focused on allergic fungal lung disease.
I am collaborating with Stanford faculty investigators including David Stevens, Jeff Wine, Alfred Spoorman, Ray Sobel and others, and colleagues at UC Berkeley and Children's Oakland Research Institute to explore the relationship and role of P. aeruginosa and A. fumigates in cystic fibrosis. This is related to ongoing work in collaboration with Lee Herzenberg and others on innate immune mechanisms operative in allergic bronchopulmonary aspergillosis, including development of a diagnostic and monitoring assay.
CF foundations of Canada, UK, Ireland, Switzerland, Germany, France, Italy
California Medical Association
I am interested in the pathogenesis of chronic airways diseases of childhood. My work includes basic and clinical research. In the area of basic research, my laboratory has focused on immunoregulation of inflammation in cystic fibrosis, finding deficiencies of activated T cells from CF patients in production of counter-regulatory cytokines (IL-10, IFN-gamma) and redox metabolism. In the arena of clinical research, as a member of the CFF Therapeutics Development Network our research group conducts many trials. I have particular interests in the areas of aerosol therapy with drugs, biologics and gene vectors; mechanisms of pulmonary inflammation and immunomodulatory therapy; and corrrection of CFTR-dependent cell biology defects. We are also investigating new treatments for CF complications such as diabetes and osteoporosis, internet-based disease management, and trials of asthma drugs. Recent projects focus on development of biomarkers and treatments for allergic fungal lung disease, e.g. inhaled antifungals.
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol
The overall objective of this study is to efficiently evaluate the clinical efficacy and
safety of different investigational therapeutics among adults who have COVID-19 but are not
yet sick enough to require hospitalization. The overall hypothesis is that through an
adaptive trial design, potential effective therapies (single and combination) may be
identified for this group of patients.
COVID-19 Outpatient Pragmatic Platform Study (COPPS) is a pragmatic platform protocol
designed to evaluate COVID-19 treatments by assessing their ability to reduce viral shedding
(Viral Domain) or improve clinical outcomes (Clinical Domain). To be included into the
platform, every investigational product will collect data for both Domain primary endpoints.
Individual treatments to be evaluated in the platform will be described in separate
Stanford is currently not accepting patients for this trial.
For more information, please contact Study Team, 650-721-9316.
View full details